PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. - Wikidata - wikimedia - TriplyDB

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

http://www.wikidata.org/entity/Q34215904

about

Targeting DNA damage response in cancer therapy Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma Targeting tumor suppressor networks for cancer therapeutics.BRCA-associated ovarian cancer: from molecular genetics to risk management 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma.Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.'BRCAness' and its implications for platinum action in gynecologic cancer.No evidence for PALB2 methylation in high-grade serous ovarian cancer.Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.Ovarian cancer: genomic analysis.Treatment related toxicity in BRCA1-associated epithelial ovarian cancer - is DNA repairing impairment associated with more adverse events?ARTD2 activity is stimulated by RNA.Olaparib, PARP1 inhibitor in ovarian cancer.Hereditary gynaecological malignancies: advances in screening and treatment.The role and clinical significance of DNA damage response and repair pathways in primary brain tumors HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion.DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.How can molecular abnormalities influence our clinical approach.

P2860

Q27023204-A425FACF-7CBB-4CF8-8A81-D93855D8D256 Q33557916-E20CC46D-1C8B-4D51-8169-190D9376A7C2 Q33631833-CB443D52-2B19-40B1-BFD3-0A68268DE897 Q33657519-9DC325D4-9996-4FD0-8640-E441397C9C7A Q34032766-DB904CE4-DC74-4599-8147-165A662736F7 Q34636501-9F9F4253-DF3B-432A-B747-E8B10499FE10 Q36245791-69ACB95D-7862-4E7C-907D-B6DB55FF42AD Q36380704-E184C375-4471-42CF-877C-BEB16F0B1BC8 Q36794191-FC55AAD9-60A3-4409-8EE6-12F6058ABEC0 Q36925152-43F59F1F-1E47-4587-A42C-F87E7CE97E15 Q37089636-A49A57E7-585D-4864-9407-18EEE514179D Q37237962-ABA7755A-F150-4C24-B9ED-E2A9EE3CFD4A Q37332480-47EAB0B5-2D6D-48BF-A7B9-286F9D853484 Q37727653-0E7EE0DC-910B-4448-B4A4-E42EAB935F5D Q37734336-5B75E835-56D9-4583-A1B1-DB1BCFC88696 Q38025738-C64AB5AB-011D-43FC-A3CB-F205CD4E0652 Q38067433-8E0FA7D3-0F3E-44B6-9555-5A50A9A38BC3 Q38079664-75B1BA78-1B0C-41F7-8E35-D6956FB0C876 Q39313548-DB66B3D6-2118-4460-AF38-5E094DC9D9EC Q41136568-673AB70C-BE7C-420E-A7BE-36DBB3EFB736 Q47862551-DF069528-6002-4B55-A637-54F7FF767AE8 Q49896005-5DB173D8-68F4-49C3-8EF4-2510E37777E6

P2860

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

http://www.wikidata.org/entity/Q34215904

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@ast

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@en

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@nl

type

label

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@ast

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@en

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@nl

prefLabel

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@ast

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@en

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@nl

P1433

Q34215904-D8F7757A-6D46-4F21-BA8F-EE1E2B087890

P1476

Q34215904-12B8119C-3112-44DB-A12A-E25D8E973EB0

P2093

Q34215904-3B8A07D0-D6B0-4C64-B2B4-D2F0051F32D9

Q34215904-606F4D17-E05E-4B3F-BA33-0C564F42771F

P2860

Q34215904-09FE29B5-C9EF-4193-88F7-B37C51862F80

Q34215904-0B984C46-6317-4E1F-96EB-2820B546ED18

Q34215904-26A267C1-52B9-4FF5-A2F7-70D7F6AE944F

Q34215904-2C8A13CC-636E-4EBC-814A-07A199D74BD7

Q34215904-3A4D352C-BA71-42AD-A1AC-D213574EA52D

Q34215904-3E320306-EA0B-46E7-B250-D6F8305DE45B

Q34215904-509D64E9-6A76-45F9-B6A4-1F522649DD56

Q34215904-52687B0C-D13B-4C41-940A-46C39462DEEC

Q34215904-55280418-8327-4C73-A4F0-7646FE13425C

Q34215904-691A00F0-71D1-4A3C-A696-8FE59C1F5477

P2888

Q34215904-E1FA7F1D-2F48-4FC7-AFF2-3A266EC57C72

P304

Q34215904-CEC68462-3E6F-4E50-B198-558D5A17E5A1

P31

Q34215904-D4A50D52-137B-42DB-8F80-DA77BFEF8C8B

P356

Q34215904-5BB885B2-429A-482D-AEE6-841788F009EC

P433

Q34215904-CBFCCE80-F475-4D7C-8761-DCD0CC55CFE4

P478

Q34215904-1A76E197-6D81-46D9-A1A7-9D1668B95873

P577

Q34215904-D73BE08B-68E9-47D0-B73A-2867ABC0930D

P6179

Q34215904-76DEA70E-B19D-42BB-8D72-61CF790C0BEF

P698

Q34215904-6A00485D-DF37-4929-B661-F643687868DE

P921

Q34215904-66CE9059-C530-4791-B923-B0E83FC262A1

P356

S11912-011-0193-9

P1433

Current Oncology Reports

P1476

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

@en

P2093

Stan Kaye

http://www.w3.org/2001/XMLSchema#string

Susana Banerjee

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Genome maintenance mechanisms for preventing cancer

The concept of synthetic lethality in the context of anticancer therapy

Resistance to therapy caused by intragenic deletion in BRCA2

Involvement of Brca2 in DNA repair

Hallmarks of 'BRCAness' in sporadic cancers

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

P2888

s11912-011-0193-9

P304

442-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-011-0193-9

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1031333294

http://www.w3.org/2001/XMLSchema#string

P698

21913063

http://www.w3.org/2001/XMLSchema#string

P921